Addex to present at biotech showcase™ 2024

Ceo to provide update on allosteric modulator pipeline clinical and preclinical development geneva, switzerland, january 5, 2024 - addex therapeutics (six and nasdaq: adxn), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that tim dyer, chief executive officer, will present at biotech showcase being held in san francisco, january 8-10, 2024. in his presentation, scheduled for monday january 8, 2024 at 4:30 pm pt (01:30 am cet), mr dyer will provide a corporate update and discuss recent advances from addex's cns pipeline, including:  adx71149 in phase 2 for epilepsy with janssen pharmaceuticals, inc. dipraglurant in post-stroke recovery gabab pam indivior strategic partnership for substance use disorders m4 pam schizophrenia program gabab pam cough program mglu2nam cognition program presentation details: date: monday, january 08 2024time: 4:30pmtrack: yosemite a (ballroom level) mr dyer will be available for one-on-one meetings throughout the conference.
ADXN Ratings Summary
ADXN Quant Ranking